TuHURA Biosciences, Inc. (HURA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.18+8.46%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge TuHURA Biosciences, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.143
Annual ending 2026-12-31
Revenue	—	10.53M
EPS	—	-0.55
Annual ending 2027-12-31
Revenue	—	22.56M
EPS	—	-0.615

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain $50 million revolving credit facility funding operations	TuHURA has a $50 million credit line to fund work until 2028.	Intact	credit facility falls below $50 million or is lost before 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce losses and improve earnings	A supporting condition in TuHURA Biosciences, Inc.'s published investment case. The stated target is EPS loss narrows from -$0.5 in 2026 to less negative.	Broken	EPS loss worsens beyond -$0.56 in FY27	Diluted EPS: $-0.14 per share FY2026-Q4; GAAP. Published target: EPS loss narrows from -$0.5 in 2026 to less negative. Target period is not explicitly aligned with this observation. Source published Aug 14, 2026-0.14 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 66cb7171-0b06-41de-996f-91852dcac2e5. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Address Nasdaq minimum bid price compliance	A primary condition in TuHURA Biosciences, Inc.'s published investment case. The stated target is Maintain bid price above Nasdaq minimum.	Under Pressure	failure to regain Nasdaq compliance leading to delisting	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.02B

Unavailable → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 3
2026-07-25	Unavailable	Unavailable	2 / 3
2026-07-26	Unavailable	Unavailable	2 / 3
2026-07-27	Unavailable	Unavailable	2 / 3
2026-07-28	Unavailable	Unavailable	2 / 3
2026-07-29	Unavailable	Unavailable	2 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	3 / 3
2026-08-01	Unavailable	Unavailable	2 / 3
2026-08-02	Unavailable	Unavailable	3 / 3
2026-08-03	Unavailable	Unavailable	3 / 3
2026-08-04	Unavailable	Unavailable	3 / 3
2026-08-05	Unavailable	Unavailable	3 / 3
2026-08-06	Unavailable	Unavailable	3 / 3
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	Unavailable	3 / 3
2026-08-09	Unavailable	Unavailable	2 / 3
2026-08-10	Unavailable	Unavailable	3 / 3
2026-08-12	Unavailable	Unavailable	3 / 3
2026-08-13	Unavailable	Unavailable	3 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	2 / 4
2026-08-23	Unavailable	Unavailable	2 / 4
2026-08-24	Unavailable	Unavailable	2 / 4
2026-08-25	Unavailable	Unavailable	2 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	$16,923,000	3 / 5
2026-08-29	Unavailable	$16,923,000	3 / 5
2026-08-30	Unavailable	$16,923,000	3 / 5
2026-08-31	Unavailable	$16,923,000	3 / 5
2026-09-01	Unavailable	$16,923,000	3 / 5
2026-09-02	Unavailable	$16,923,000	3 / 5
2026-09-03	Unavailable	$16,923,000	3 / 5
2026-09-04	Unavailable	$16,923,000	3 / 5
2026-09-05	Unavailable	$22,564,000	3 / 5
2026-09-06	Unavailable	$22,564,000	3 / 5
2026-09-07	Unavailable	$22,564,000	3 / 5
2026-09-08	Unavailable	$22,564,000	3 / 5
2026-09-09	Unavailable	$22,564,000	3 / 5
2026-09-10	Unavailable	$22,564,000	3 / 5
2026-09-11	Unavailable	$22,564,000	3 / 5
2026-09-12	Unavailable	$22,564,000	3 / 5
2026-09-13	Unavailable	$22,564,000	3 / 5
2026-09-14	Unavailable	$22,564,000	3 / 5
2026-09-15	Unavailable	$22,564,000	3 / 5
2026-09-16	Unavailable	$22,564,000	3 / 5
2026-09-17	Unavailable	$22,564,000	3 / 5
2026-09-18	Unavailable	$22,564,000	3 / 5
2026-09-19	Unavailable	$22,564,000	3 / 5
2026-09-20	Unavailable	$22,564,000	3 / 5
2026-09-21	Unavailable	$22,564,000	3 / 5
2026-09-22	Unavailable	$22,564,000	3 / 5
2026-09-23	Unavailable	$22,564,000	3 / 5
2026-09-24	Unavailable	$22,564,000	3 / 5
2026-09-25	Unavailable	$22,564,000	3 / 5
2026-09-26	Unavailable	$22,564,000	3 / 5
2026-09-27	Unavailable	$22,564,000	3 / 5
2026-09-28	Unavailable	$22,564,000	3 / 5
2026-09-29	Unavailable	$22,564,000	3 / 5
2026-09-30	Unavailable	$22,564,000	3 / 5
2026-10-01	Unavailable	$22,564,000	3 / 5
2026-10-02	Unavailable	$22,564,000	3 / 5
2026-10-03	Unavailable	$22,564,000	3 / 5
2026-10-04	Unavailable	$22,564,000	3 / 5
2026-10-05	Unavailable	$22,564,000	3 / 5
2026-10-06	Unavailable	$22,564,000	3 / 5
2026-10-07	Unavailable	$22,564,000	3 / 5
2026-10-08	Unavailable	$22,564,000	3 / 5
2026-10-09	Unavailable	$22,564,000	3 / 5
2026-10-10	Unavailable	$22,564,000	3 / 5
2026-10-11	Unavailable	$22,564,000	3 / 5
2026-10-12	Unavailable	$22,564,000	3 / 5
2026-10-13	Unavailable	$22,564,000	3 / 5
2026-10-14	Unavailable	$22,564,000	3 / 5
2026-10-15	Unavailable	$22,564,000	3 / 5
2026-10-16	Unavailable	$22,564,000	3 / 5
2026-10-17	Unavailable	$22,564,000	3 / 5
2026-10-18	Unavailable	$22,564,000	3 / 5
2026-10-19	Unavailable	$22,564,000	3 / 5
2026-10-20	Unavailable	$22,564,000	3 / 5
2026-10-21	Unavailable	$22,564,000	3 / 5
2026-10-22	Unavailable	$22,564,000	3 / 5
2026-10-23	Unavailable	$22,564,000	3 / 5
2026-10-24	Unavailable	$22,564,000	3 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	0	0
2026-06-01	4	0	0
2026-07-01	4	0	0
2026-08-01	4	0	0
2026-09-01	4	0	0
2026-10-01	4	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain $50 million revolving credit facility funding operationsDirect metric needs a verified mapping
Reduce losses and improve earningsPublished status: Broken
Address Nasdaq minimum bid price compliancePublished status: Under Pressure

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-82.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

TuHURA Biosciences, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

HURA is a speculative, loss-making biotechnology company rather than an established compounder. Its long-term thesis is on watch: clinical programs are advancing, but recent financial performance is weak and management execution is rated volatile.

What's priced into TuHURA Biosciences, Inc.

The snapshot provides no valuation or market-expectations evidence, so whether HURA is cheap or expensive versus peers cannot be assessed. Its muted recent price reaction does not resolve that gap or change the weak fundamental picture.

What the fundamentals likely do

Near term, clinical activity may continue to rise: management says key programs are advancing, and research and development spending increased through 2026-Q2. Funding remains a concern, with cash falling to $1.0 million at 2026-Q2 and $5.7 million drawn on the credit facility by 2026-Q3; recent financial-obligation filings add to that concern. The next company update carries meaningful execution risk, and the snapshot flags a high chance of a miss without specifying a forecast.

What TuHURA Biosciences, Inc. hinges on

The multi-year thesis hinges on delivery of clinical milestones, including those expected in the second half of 2026 and in 2027, and progress toward the anticipated orphan drug designations. Near-term, a guidance cut would be a negative, while continued strength among healthcare bellwethers could support the sector backdrop. Continued weakening in the jobs data could weigh on cyclical and healthcare names, though the snapshot gives limited detail on HURA’s specific sensitivity.